GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (NAS:EOLS) » Definitions » Piotroski F-Score

Evolus (Evolus) Piotroski F-Score : 4 (As of Apr. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Evolus Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Evolus has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Evolus's Piotroski F-Score or its related term are showing as below:

EOLS' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 4
Current: 4

During the past 9 years, the highest Piotroski F-Score of Evolus was 4. The lowest was 2. And the median was 3.


Evolus Piotroski F-Score Historical Data

The historical data trend for Evolus's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus Piotroski F-Score Chart

Evolus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only 2.00 3.00 4.00 2.00 4.00

Evolus Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 3.00 4.00 4.00 4.00

Competitive Comparison of Evolus's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolus's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Evolus's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -14.791 + -18.14 + -16.923 + -11.831 = $-61.7 Mil.
Cash Flow from Operations was -20.587 + -13.31 + -0.924 + 0.813 = $-34.0 Mil.
Revenue was 41.721 + 49.346 + 50.019 + 60.999 = $202.1 Mil.
Gross Profit was 29.575 + 34.634 + 34.588 + 41.729 = $140.5 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(177.983 + 160.235 + 168.983 + 167.971 + 188.998) / 5 = $172.834 Mil.
Total Assets at the begining of this year (Dec22) was $178.0 Mil.
Long-Term Debt & Capital Lease Obligation was $125.2 Mil.
Total Current Assets was $112.4 Mil.
Total Current Liabilities was $48.3 Mil.
Net Income was -17.501 + -23.471 + -20.276 + -13.164 = $-74.4 Mil.

Revenue was 33.908 + 37.163 + 33.899 + 43.646 = $148.6 Mil.
Gross Profit was 20.7 + 21.344 + 20.409 + 30.276 = $92.7 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(257.483 + 220.662 + 210.919 + 192.719 + 177.983) / 5 = $211.9532 Mil.
Total Assets at the begining of last year (Dec21) was $257.5 Mil.
Long-Term Debt & Capital Lease Obligation was $73.1 Mil.
Total Current Assets was $100.8 Mil.
Total Current Liabilities was $46.5 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Evolus's current Net Income (TTM) was -61.7. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Evolus's current Cash Flow from Operations (TTM) was -34.0. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-61.685/177.983
=-0.34657804

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-74.412/257.483
=-0.28899772

Evolus's return on assets of this year was -0.34657804. Evolus's return on assets of last year was -0.28899772. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Evolus's current Net Income (TTM) was -61.7. Evolus's current Cash Flow from Operations (TTM) was -34.0. ==> -34.0 > -61.7 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=125.169/172.834
=0.72421514

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=73.103/211.9532
=0.34490161

Evolus's gearing of this year was 0.72421514. Evolus's gearing of last year was 0.34490161. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=112.421/48.291
=2.32799072

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=100.802/46.509
=2.16736546

Evolus's current ratio of this year was 2.32799072. Evolus's current ratio of last year was 2.16736546. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Evolus's number of shares in issue this year was 57.25. Evolus's number of shares in issue last year was 56.269. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=140.526/202.085
=0.69538066

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=92.729/148.616
=0.62395031

Evolus's gross margin of this year was 0.69538066. Evolus's gross margin of last year was 0.62395031. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=202.085/177.983
=1.13541743

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=148.616/257.483
=0.57718762

Evolus's asset turnover of this year was 1.13541743. Evolus's asset turnover of last year was 0.57718762. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+1+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Evolus has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Evolus  (NAS:EOLS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Evolus Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Evolus's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolus (Evolus) Business Description

Traded in Other Exchanges
Address
520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare, or commercial insurance. It generates product revenue from the sale of Jeuveau in the United States.
Executives
David Moatazedi director, officer: See Remarks C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Medytox Inc. 10 percent owner 78, GANGNI 1-GIL, OCHANG-EUP,, CHEONGWON-GU, CHEOGJU-SI M5 28126
Sandra Beaver officer: Chief Financial Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Tomoko Yamagishi-dressler officer: Chief Marketing Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Rui Avelar officer: See Remarks 1618 STATION STREET, VANCOUVER A1 V6A 1B6
Vikram Malik director 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Alphaeon 1 Llc 10 percent owner 4040 MACARTHUR BOULEVARD, SUITE 310, NEWPORT BEACH CA 92660
Robert Hayman director 8550 HIGUERA ST, CULVER CITY CA 90232
Simone Blank director C/O SIRONA, WASSERFELDSTRASSE 30 A-5020, SALZBURG C4 5020
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Lauren P Silvernail officer: See Remarks 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Crystal Muilenburg officer: Chief Marketing Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Brady Stewart director 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Michael M. Jafar officer: Chief Marketing Officer 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614